reason report
preview expect quarter put take
bottom line report earn close
thursday may call et dial
passcod peer-lead medic safeti manag
platform provid play ade advers drug event mitig
popul age believ remain intact independ
macro note even assum new win still
pois grow top line driven steadi growth
pace revenu though covid present near term headwind
pharmaci revenu model pt drag revenue growth
believ pandem longer term net posit impact
pace program all-inclus elderli busi
popul shift altern senior care beyond nurs home
share ytd vs flat perform hcit peer ex
op believ investor place premium steadi
highli visibl revenu gener like believ line
quarter posit management commentari pace outlook
enough share reiter outperform rate pt
watch item covid impact pace market look call
management color covid put take pace market
make trhc revenu although expect downtick
new pace center open pandem post-covid believ
enrol could see uplift popul shift altern senior
care beyond nurs home note temporarili relax
certain step member enrol process due covid video
conferenc intak assess verbal signatur allow
easier sign process potenti help organ enrol
store sale basi accord data integr
resourc center nationwid pace enrol
april vs march show flattish still posit
enrol trend note trhc histor growth rate
pace includ growth exist busi set healthi
floor growth even see drop new pace center start
watch item covid impact pharmaci market expect
meaning headwind covid trhc pharmaci revenu
note pharmaci revenu typic see level season
uptick driven year cancel pharmaci
confer model revenu headwind pharmaci
end market repres point headwind segment growth
line street rev adj ebitda model
revenu reflect growth y/i organ ex
prescribewel line street estimate note organ
net debt total capit
price-to-earnings lt ep growth
multipl revenu
year price history/av daili volume mil
compani inform svb leerink llc research
pleas refer page import disclosur price chart analyst certif
revenue growth repres pt deceler sequenti driven
lack benefit rate threshold chang vs last year
loss servic revenu contract cancel
adj ebitda line street averag ex prior
guid estimate guidanc adj ebitda estimate
reflect margin reflect compress servic
revenu soft high decrement margin exacerb
contract cancel
expect new segment result per manag
guidanc compani introduc new segment mention
januari investor day print compar exist
product/servic segment revenu divid pace
non-pac segment view posit closer
exist investor thought process around name believ pace
segment includ rev mrm prescript fulfil servic
partial rev mrm servic non-pac segment contain
revenu current segment model servic
revenu growth organ contract
cancel product growth new segment
estim growth pace revenu line guidanc
growth non-pac revenu organ
updat model post earn reflect new segment
lower estim covid updat estim
reflect impact covid trhc pace pharmaci busi
lower revenue estimate prior
covid impact pharmaci revenu driven pandem relat
cancel pharmaci confer histor deriv
impact pt drag top line growth vs growth prior
revenu estimate move due knock-on
effect pharmaci busi declin revenu growth move
easier prior year comp
watch item call color covid impact
busi line lt outlook pace market revenu growth
updat new win activ pipelin color cross sell traction
covid
peer lead medic risk manag solut trade discount high-growth peer
oper peer-lead medic safeti manag platform sold primarili
pace program all-inclus elderli mtm emtm end market believ
trhc secular ade advers drug event mitig stori remain intact independ
macro see clear path growth mid-term high degre visibl
trade nearli two-turn discount high growth peer initi
outperform rate pt impli upsid
current trade ntm revenu line histor averag
revenu two turn high growth hcit peer top line price
target appli multipl revenu effect roll forward current level
downsid risk estim price target includ
impact pace enrol
competit pressur new entrant
million excep per share data
total cost revenu
research develop
sale market
gener administr
depreci amort
chang fair valu acquisition-rel conting consider
non- reconcili
net incom loss attribut common stockhold dilut
payrol tax expens relat stock option excercis
chang fair valu acquisition-rel conting consider
payrol tax expens relat stock option excercis
chang fair valu acquisition-rel conting consider
compani inform svb leerink llc
